

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10581000
	Filing Date		2007-05-10
	First Named Inventor	Rudiger Woscholski	
	Art Unit	1614	
	Examiner Name		
	Attorney Docket Number	4033.3003 US	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030055106	A1	2003-03-20	Faure, Robert et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	00/57860	WO	A2	2000-10-05	Centre for Translational Research in Cancer, Can.		<input type="checkbox"/>
	2	2004/018655	WO	A2	2004-03-04	Neuronova AB, Swed.		<input type="checkbox"/>
	3	2 396 106	GB	A	2004-06-16	Johnson & Johnson Medical Limited, UK		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10581000
Filing Date	2007-05-10
First Named Inventor	Rudiger Woscholski
Art Unit	1614
Examiner Name	
Attorney Docket Number	4033.3003 US

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	SCHMID, Annette C., et al., "Bisperoxovanadium compounds are potent PTEN inhibitors," FEBS Letters, 566: 35-38 (2004).	<input type="checkbox"/>
	2	NOLTE, Lorraine A., et al., "A peroxovanadium compound stimulates muscle glucose transport as powerfully as insulin and contractions combined," Diabetes, 52(8): 1918-1925 (2003).	<input type="checkbox"/>
	3	BAND, Christian J., et al., "Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen)," Molecular Endocrinology, 11(13): 1889-1910 (1997).	<input type="checkbox"/>
	4	BAND, Christian J. and POSNER, Barry I., "Phosphatidylinositol 3'-Kinase and p70s6k are Required for Insulin but not Bisperoxovanadium 1, 10-phenanthroline (bpv(phen)) Inhibition of Insulin-like Growth Factor Binding Protein Gene Expression," J. Biological Chemistry, 272(1): 138-145 (1997).	<input type="checkbox"/>
	5	BARAT, Corrine and TREMBLAY, Michael J., "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene," J. Biological Chemistry, 278(9): 6992-7000 (2002).	<input type="checkbox"/>
	6	SASAGAWA, Takahiro, et al., "Bis(6-ethylpicolinate)oxovanadium(IV) Complex with Normoglycemic Activity in KK-Ay Mice," J. Inorganic Biochemistry, 88(1): 108-112 (2002).	<input type="checkbox"/>
	7	KOZLOV, Alexander, et al., "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations," J. Molecular Catalysis A: Chemical, 137: 223-237 (1999).	<input type="checkbox"/>
	8	POSNER, B.I., et al., "Peroxovanadium Compounds. A New Class of Potent Phosphotyrosine Phosphatase Inhibitors Which are Insulin Mimetics, J. Biol. Chem., 269 (6): 4596-4604 (1994).	<input type="checkbox"/>
	9	CUNCIC, C., et al., "Vanadate Inhibition of Protein Tyrosine Phosphatases in Jurkat Cells: Modulation by Redox State," J. Biol. Inorg. Chem., 4: 354-359 (1999).	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10581000
	Filing Date		2007-05-10
	First Named Inventor	Rudiger Woscholski	
	Art Unit		1614
	Examiner Name		
	Attorney Docket Number		4033.3003 US

10	HUYER, G., et al., "Mechanism of Inhibition of Protein-Tyrosine Phosphatases by Vanadate and Pervanadate," J. Biol. Chem., 272(2): 843-851 (1997).	<input type="checkbox"/>
11	RUMORA, L., et al., "Differential Regulation of JNK Activation and MKP-1 Expression by Peroxovanadium Complexes," Neurochem. Int., 38: 341-347 (2001).	<input type="checkbox"/>
12	SHISHEVA, A. and SHECHTER, Y., et al., "Mechanism of Pervanadate Stimulation and Potentiation of Insulin-Activated Glucose Transport in Rat Adipocytes: Dissociation from Vanadate Effect," Endocrinology, 133(4): 1562-1568 (1993).	<input type="checkbox"/>
13	WILDEN, P.A.. and BROADWAY, D., "Combination of Insulinomimetic Agents H2O2 and Vanadate Enhances Insulin Receptor Mediated Tyrosine Phosphorylation of IRS-1 Leading to IRS-1 Association with the Phosphatidylinositol 3-kinase," J. Cell Biochem., 58: 279-291 (1995).	<input type="checkbox"/>
14	SHECHTER, Y., "Insulin-Mimetic Effects of Vanadate. Possible Implications for Future Treatment of Diabetes," Diabetes, 39: 1-5 (1990).	<input type="checkbox"/>
15	STEPHENS, L.R., et al., "Agonist-Stimulated Synthesis of Phosphatidylinositol(3,4,5)-Trisphosphate: A New Intracellular Signalling System?" Biochim. et Biophys. Acta, 1179: 27-75 (1993).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.